Annual EBIT
-$164.02 M
-$64.85 M-65.40%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual earnings before interest & taxes is -$164.02 million, with the most recent change of -$64.85 million (-65.40%) on December 31, 2023.
- During the last 3 years, LXRX annual EBIT has fallen by -$119.99 million (-272.51%).
- LXRX annual EBIT is now -213.28% below its all-time high of $144.79 million, reached on December 31, 2019.
Performance
LXRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$60.25 M
-$9.03 M-17.63%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly earnings before interest & taxes is -$60.25 million, with the most recent change of -$9.03 million (-17.63%) on September 30, 2024.
- Over the past year, LXRX quarterly EBIT has dropped by -$16.80 million (-38.67%).
- LXRX quarterly EBIT is now -126.74% below its all-time high of $225.28 million, reached on September 30, 2019.
Performance
LXRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$199.25 M
-$13.62 M-7.34%
September 30, 2024
Summary
- As of February 7, 2025, LXRX TTM earnings before interest & taxes is -$199.25 million, with the most recent change of -$13.62 million (-7.34%) on September 30, 2024.
- Over the past year, LXRX TTM EBIT has dropped by -$21.90 million (-12.35%).
- LXRX TTM EBIT is now -211.20% below its all-time high of $179.18 million, reached on September 30, 2019.
Performance
LXRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
LXRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.4% | -38.7% | -12.3% |
| 3 y3 years | -272.5% | -167.5% | -109.5% |
| 5 y5 years | -64.4% | -126.7% | -237.6% |
LXRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.6% | at low | -167.5% | at low | -129.1% | at low |
| 5 y | 5-year | -213.3% | at low | -169.5% | +5.8% | -237.6% | at low |
| alltime | all time | -213.3% | at low | -126.7% | +5.8% | -211.2% | at low |
Lexicon Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$60.25 M(+17.6%) | -$199.25 M(+7.3%) |
| Jun 2024 | - | -$51.22 M(+17.9%) | -$185.63 M(+4.7%) |
| Mar 2024 | - | -$43.45 M(-2.0%) | -$177.35 M(+8.1%) |
| Dec 2023 | -$164.02 M(+65.4%) | -$44.34 M(-4.9%) | -$164.02 M(+10.0%) |
| Sep 2023 | - | -$46.63 M(+8.6%) | -$149.07 M(+19.3%) |
| Jun 2023 | - | -$42.94 M(+42.6%) | -$124.97 M(+18.0%) |
| Mar 2023 | - | -$30.11 M(+2.5%) | -$105.91 M(+6.8%) |
| Dec 2022 | -$99.16 M(+14.0%) | -$29.39 M(+30.5%) | -$99.16 M(+4.3%) |
| Sep 2022 | - | -$22.52 M(-5.7%) | -$95.09 M(-0.4%) |
| Jun 2022 | - | -$23.88 M(+2.2%) | -$95.52 M(+6.7%) |
| Mar 2022 | - | -$23.37 M(-7.7%) | -$89.53 M(+3.0%) |
| Dec 2021 | -$86.96 M(+97.5%) | -$25.32 M(+10.3%) | -$86.96 M(+29.9%) |
| Sep 2021 | - | -$22.95 M(+28.2%) | -$66.97 M(-256.8%) |
| Jun 2021 | - | -$17.90 M(-13.9%) | $42.71 M(-1378.3%) |
| Mar 2021 | - | -$20.79 M(+290.4%) | -$3.34 M(-92.4%) |
| Dec 2020 | -$44.03 M(-130.4%) | -$5.33 M(-106.1%) | -$44.03 M(-48.0%) |
| Sep 2020 | - | $86.72 M(-235.6%) | -$84.65 M(-257.0%) |
| Jun 2020 | - | -$63.95 M(+4.0%) | $53.90 M(-46.1%) |
| Mar 2020 | - | -$61.48 M(+33.8%) | $100.00 M(-30.9%) |
| Dec 2019 | $144.79 M(-245.1%) | -$45.95 M(-120.4%) | $144.79 M(-19.2%) |
| Sep 2019 | - | $225.28 M(-1361.8%) | $179.18 M(-362.6%) |
| Jun 2019 | - | -$17.85 M(+7.0%) | -$68.24 M(-14.4%) |
| Mar 2019 | - | -$16.68 M(+44.3%) | -$79.74 M(-20.1%) |
| Dec 2018 | -$99.77 M(-22.5%) | -$11.56 M(-47.8%) | -$99.77 M(-11.2%) |
| Sep 2018 | - | -$22.14 M(-24.6%) | -$112.38 M(-5.8%) |
| Jun 2018 | - | -$29.36 M(-20.0%) | -$119.34 M(-3.3%) |
| Mar 2018 | - | -$36.71 M(+51.9%) | -$123.42 M(-4.1%) |
| Dec 2017 | -$128.67 M(+3.0%) | -$24.17 M(-17.0%) | -$128.67 M(+2.7%) |
| Sep 2017 | - | -$29.10 M(-13.0%) | -$125.30 M(-4.0%) |
| Jun 2017 | - | -$33.45 M(-20.3%) | -$130.57 M(-2.3%) |
| Mar 2017 | - | -$41.95 M(+101.7%) | -$133.60 M(+7.0%) |
| Dec 2016 | -$124.88 M(-6221.5%) | -$20.80 M(-39.5%) | -$124.88 M(+698.0%) |
| Sep 2016 | - | -$34.37 M(-5.8%) | -$15.65 M(+5.2%) |
| Jun 2016 | - | -$36.47 M(+9.7%) | -$14.88 M(+208.6%) |
| Mar 2016 | - | -$33.23 M(-137.6%) | -$4.82 M(-336.3%) |
| Dec 2015 | $2.04 M(-102.1%) | $88.43 M(-363.2%) | $2.04 M(-102.3%) |
| Sep 2015 | - | -$33.59 M(+27.2%) | -$88.50 M(-6.8%) |
| Jun 2015 | - | -$26.42 M(+0.2%) | -$94.95 M(+0.9%) |
| Mar 2015 | - | -$26.37 M(+1149.4%) | -$94.11 M(-4.1%) |
| Dec 2014 | -$98.11 M(-4.0%) | -$2.11 M(-94.7%) | -$98.11 M(-13.1%) |
| Sep 2014 | - | -$40.05 M(+56.6%) | -$112.94 M(+8.5%) |
| Jun 2014 | - | -$25.57 M(-15.8%) | -$104.05 M(-2.8%) |
| Mar 2014 | - | -$30.38 M(+79.4%) | -$107.06 M(+4.8%) |
| Dec 2013 | -$102.16 M(-5.5%) | -$16.94 M(-45.7%) | -$102.16 M(-6.8%) |
| Sep 2013 | - | -$31.17 M(+9.0%) | -$109.57 M(+2.0%) |
| Jun 2013 | - | -$28.58 M(+12.2%) | -$107.42 M(+3.1%) |
| Mar 2013 | - | -$25.47 M(+4.6%) | -$104.23 M(-3.6%) |
| Dec 2012 | -$108.10 M | -$24.35 M(-16.1%) | -$108.10 M(-7.6%) |
| Sep 2012 | - | -$29.01 M(+14.2%) | -$117.04 M(+3.1%) |
| Jun 2012 | - | -$25.40 M(-13.4%) | -$113.57 M(-0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$29.33 M(-11.9%) | -$114.09 M(+0.2%) |
| Dec 2011 | -$113.69 M(+14.7%) | -$33.29 M(+30.3%) | -$113.90 M(+10.6%) |
| Sep 2011 | - | -$25.54 M(-1.5%) | -$102.98 M(-1.3%) |
| Jun 2011 | - | -$25.93 M(-11.0%) | -$104.34 M(+1.8%) |
| Mar 2011 | - | -$29.14 M(+30.2%) | -$102.48 M(+4.2%) |
| Dec 2010 | -$99.08 M(+9.5%) | -$22.37 M(-16.8%) | -$98.31 M(+0.4%) |
| Sep 2010 | - | -$26.90 M(+11.7%) | -$97.93 M(+5.3%) |
| Jun 2010 | - | -$24.07 M(-3.6%) | -$93.01 M(+1.4%) |
| Mar 2010 | - | -$24.97 M(+13.6%) | -$91.72 M(+1.5%) |
| Dec 2009 | -$90.45 M(-4.0%) | -$21.98 M(-0.0%) | -$90.32 M(+4.0%) |
| Sep 2009 | - | -$21.98 M(-3.5%) | -$86.88 M(-3.2%) |
| Jun 2009 | - | -$22.78 M(-3.3%) | -$89.72 M(-3.9%) |
| Mar 2009 | - | -$23.57 M(+27.1%) | -$93.33 M(-0.9%) |
| Dec 2008 | -$94.19 M(+25.7%) | -$18.55 M(-25.3%) | -$94.19 M(+0.1%) |
| Sep 2008 | - | -$24.82 M(-5.9%) | -$94.11 M(+6.1%) |
| Jun 2008 | - | -$26.39 M(+8.0%) | -$88.73 M(+10.5%) |
| Mar 2008 | - | -$24.44 M(+32.3%) | -$80.30 M(+7.1%) |
| Dec 2007 | -$74.95 M(+35.7%) | -$18.47 M(-5.0%) | -$74.95 M(+5.5%) |
| Sep 2007 | - | -$19.44 M(+8.3%) | -$71.06 M(+10.5%) |
| Jun 2007 | - | -$17.95 M(-6.0%) | -$64.32 M(+1.6%) |
| Mar 2007 | - | -$19.09 M(+31.0%) | -$63.31 M(+14.6%) |
| Dec 2006 | -$55.23 M(+52.9%) | -$14.57 M(+14.7%) | -$55.23 M(+58.1%) |
| Sep 2006 | - | -$12.71 M(-25.0%) | -$34.94 M(-3.7%) |
| Jun 2006 | - | -$16.93 M(+53.7%) | -$36.29 M(+7.1%) |
| Mar 2006 | - | -$11.02 M(-292.6%) | -$33.87 M(-6.2%) |
| Dec 2005 | -$36.12 M(-23.9%) | $5.72 M(-140.7%) | -$36.12 M(-16.6%) |
| Sep 2005 | - | -$14.05 M(-3.2%) | -$43.30 M(+0.2%) |
| Jun 2005 | - | -$14.52 M(+9.4%) | -$43.19 M(-4.3%) |
| Mar 2005 | - | -$13.27 M(+809.9%) | -$45.12 M(-4.9%) |
| Dec 2004 | -$47.45 M(-24.2%) | -$1.46 M(-89.5%) | -$47.45 M(-18.7%) |
| Sep 2004 | - | -$13.95 M(-15.2%) | -$58.34 M(-1.6%) |
| Jun 2004 | - | -$16.44 M(+5.4%) | -$59.26 M(-2.3%) |
| Mar 2004 | - | -$15.60 M(+26.4%) | -$60.66 M(-3.1%) |
| Dec 2003 | -$62.59 M(-0.5%) | -$12.34 M(-17.0%) | -$62.59 M(-3.5%) |
| Sep 2003 | - | -$14.87 M(-16.7%) | -$64.84 M(-3.9%) |
| Jun 2003 | - | -$17.85 M(+1.8%) | -$67.46 M(+3.4%) |
| Mar 2003 | - | -$17.53 M(+20.2%) | -$65.25 M(+3.7%) |
| Dec 2002 | -$62.89 M(+44.1%) | -$14.59 M(-16.6%) | -$62.89 M(+3.2%) |
| Sep 2002 | - | -$17.49 M(+11.8%) | -$60.93 M(+18.6%) |
| Jun 2002 | - | -$15.64 M(+3.1%) | -$51.40 M(+7.1%) |
| Mar 2002 | - | -$15.18 M(+20.2%) | -$47.99 M(+10.0%) |
| Dec 2001 | -$43.64 M(+23.0%) | -$12.63 M(+58.7%) | -$43.64 M(+4.3%) |
| Sep 2001 | - | -$7.95 M(-35.0%) | -$41.85 M(+7.9%) |
| Jun 2001 | - | -$12.24 M(+13.1%) | -$38.79 M(+18.0%) |
| Mar 2001 | - | -$10.82 M(-0.2%) | -$32.86 M(-7.4%) |
| Dec 2000 | -$35.48 M(+177.2%) | -$10.84 M(+121.7%) | -$35.48 M(+44.0%) |
| Sep 2000 | - | -$4.89 M(-22.5%) | -$24.64 M(+24.8%) |
| Jun 2000 | - | -$6.31 M(-53.0%) | -$19.75 M(+47.0%) |
| Mar 2000 | - | -$13.44 M | -$13.44 M |
| Dec 1999 | -$12.80 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual EBIT year-on-year change?
- What is Lexicon Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly EBIT year-on-year change?
- What is Lexicon Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM EBIT year-on-year change?
What is Lexicon Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of LXRX is -$164.02 M
What is the all time high annual EBIT for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual earnings before interest & taxes is $144.79 M
What is Lexicon Pharmaceuticals annual EBIT year-on-year change?
Over the past year, LXRX annual earnings before interest & taxes has changed by -$64.85 M (-65.40%)
What is Lexicon Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of LXRX is -$60.25 M
What is the all time high quarterly EBIT for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly earnings before interest & taxes is $225.28 M
What is Lexicon Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, LXRX quarterly earnings before interest & taxes has changed by -$16.80 M (-38.67%)
What is Lexicon Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of LXRX is -$199.25 M
What is the all time high TTM EBIT for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM earnings before interest & taxes is $179.18 M
What is Lexicon Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, LXRX TTM earnings before interest & taxes has changed by -$21.90 M (-12.35%)